(R)-2-(3,4-difluorophenyl)-2-hydroxyacetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(3,4-difluorophenyl)-2-hydroxyacetic acid
• 英文别名: (2R)-(3,4-difluorophenyl)(hydroxy)acetic acid；(2R)-2-(3,4-difluorophenyl)-2-hydroxyacetic acid
• 化学式: C₈H₆F₂O₃
• 分子量: 188.131
• InChiKey: BKHXODARAOCNDJ-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-二氟苯甲醛 、 聚甘氨酸 在 escherichia coli whole cells harboring phenylserine aldolase_phenylserine dehydratase_hydroxyphenylpyruvate dioxygenase mutant S₂₀₁V 作用下， 以 aq. phosphate buffer 、 水 、 二甲基亚砜 为溶剂， 以75 %的产率得到(R)-2-(3,4-difluorophenyl)-2-hydroxyacetic acid
  参考文献：
  名称：

  醛类的不对称 C1 延伸通过生物催化级联立体合成扁桃酸

  摘要：

  由 L-苏氨酸醛缩酶 (LTA)、L-苏氨酸脱水酶 (LTD) 和 4-羟基扁桃酸合酶 (HmaS) 组成的生物催化级联被开发用于无氰化物不对称 C 1延伸。中心酶 HmaS 的工程化使得能够从甘氨酸和芳香醛中立体合成扁桃酸。

  DOI：

  10.1002/anie.202300906

文献信息

• MANDELIC HYDRAZIDES
  申请人：Gericke Rolf

  公开号：US20090221712A1

  公开（公告）日：2009-09-03

  Novel mandelic hydrazides of the formula (I), in which R 1 -R 11 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

  式(I)中的新颖杏仁酸肼化合物，其中R1-R11具有权利要求1中指示的含义，是SGK抑制剂，可用于治疗SGK诱导的疾病和症状，如糖尿病、肥胖、代谢综合征（血脂异常）、全身和肺动脉高压、心血管疾病和肾脏疾病，一般在任何类型的纤维化和炎症过程中。
• [EN] SUBSTITUTED alpha -HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF<br/>[FR] ACIDES alpha -HYDROXY SUBSTITUES INHIBITEURS DE CASPASES ET LEURS UTILISATIONS
  申请人：CYTOVIA INC

  公开号：WO2001016093A1

  公开（公告）日：2001-03-08

  The present invention is directed to novel substituted α-hydroxy acid thereof, represented by general Formula (I), where R1-R5, X and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

  本发明涉及一种新的取代α-羟基酸及其衍生物，其通式表示为（I），其中R1-R5，X和Z的定义如本文所述。本发明还涉及到化合物具有公式（I），是半胱天冬酶和凋亡细胞死亡的有效抑制剂的发现。因此，本发明的抑制剂可以延缓或阻止在细胞、组织或整个器官丢失的多种临床情况中的细胞死亡。
• NEW AMINO ACID DERIVATIVES
  申请人：AstraZeneca AB

  公开号：US20040087647A1

  公开（公告）日：2004-05-06

  There is provided amino acid derivatives of formula I, 1 wherein p, q, R 1 , R 2 , R 3 , R 4 , Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了公式I，其中p，q，R1，R2，R3，R4，Y，n和B具有在描述中给出的含义，这些衍生物可用作类似胰蛋白酶的竞争性抑制剂，如凝血酶，并特别用于治疗需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• Amino acid derivatives
  申请人：Astra AB

  公开号：US20020042396A1

  公开（公告）日：2002-04-11

  There is provided amino acid derivatives of formula I, 1 wherein p, q, R 1 , R 2 , R 3 , R 4 , Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as hirombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了公式I,1的氨基酸衍生物，其中p，q，R1，R2，R3，R4，Y，n和B的含义如描述中所示，可作为类似胰蛋白酶的竞争性抑制剂，例如hirombin，并且特别适用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂的治疗。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。